UNSPSC 51293612: Binedaline hydrochloride

This classification denotes an antidepressant agent with the molecular formula C19H23N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WEK9FVT37G, chemically known as n,n,n-trimethyl-n-(3-phenyl-1h-indol-1-yl)ethylenediamine monohydrochloride but more generally known as binedaline hydrochloride, which bears US NIH Compound Identifier 42509. European Medicines Agency schedules Binedaline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25841.

Most nations, for tariff and trade purposes, schedule binedaline hydrochloride under HS 29339990. As of Q4 2014, BINEDALINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCN(C)N1CC(C2C1CCCC2)C3CCCCC3.CL.

UNSPSC 51293612 Binedaline hydrochloride is a Commodity code that encompasses pharmaceutical active pharmaceutical ingredients and their preparations, though the recent state and local opportunities recorded under this code actually involve naloxone, therapeutic pharmacy direct-to-manufacturer programs, and generic multi-source pharmaceuticals rather than binedaline specifically. State and local buying under this code spans public health departments and health and human services agencies procuring emergency response medications (naloxone for opioid overdose reversal), establishing pharmacy benefit management infrastructure, and sourcing generic and over-the-counter pharmaceutical products for distribution across government health systems. Issuing bodies include county public health departments (such as Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating states including Minnesota and Oregon). These entities typically structure pharmaceutical procurements as competitive bids or requests for proposal with multi-year contract terms, performance requirements tied to FDA compliance and drug supply chain security, and established wholesaler distribution networks.

Recent activity appears concentrated in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries through July 2026, structured on a two-year term with optional one-year renewal and fixed-fee pricing. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor information on direct-to-manufacturer prescription programs to inform future formal solicitation strategy. The Minnesota Department of Administration, administering the MMCAP cooperative purchasing vehicle, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products with a March 26, 2026 proposal deadline, serving multiple participating states with award effective July 1, 2026. Vendors responding to these opportunities must typically hold current Good Manufacturing Practices certification, comply with Drug Supply Chain Security Act requirements, maintain specified insurance coverage including general liability, and meet E-Verify employment eligibility verification standards.